Recent advances and challenges in antibacterial drug development; The editorial

Silver, Lynn L.

doi:10.5599/admet.1315

Cited by 2 publications

(2 citation statements)

References 11 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recognizing that chemical-genetic signatures are unique to each species offers an opportunity to expedite the creation of specific drug combinations. These precisely targeted approaches can amplify the efficacy of antibiotics and enhance AMR management (Silver, 2022 ).…”

Section: Strategies For Combating Antimicrobial Resistancementioning

confidence: 99%

Understanding bacterial pathogenicity: a closer look at the journey of harmful microbes

Soni,

Sinha,

Pandey

2024

Front. Microbiol.

View full text Add to dashboard Cite

Bacteria are the most prevalent form of microorganisms and are classified into two categories based on their mode of existence: intracellular and extracellular. While most bacteria are beneficial to human health, others are pathogenic and can cause mild to severe infections. These bacteria use various mechanisms to evade host immunity and cause diseases in humans. The susceptibility of a host to bacterial infection depends on the effectiveness of the immune system, overall health, and genetic factors. Malnutrition, chronic illnesses, and age-related vulnerabilities are the additional confounders to disease severity phenotypes. The impact of bacterial pathogens on public health includes the transmission of these pathogens from healthcare facilities, which contributes to increased morbidity and mortality. To identify the most significant threats to public health, it is crucial to understand the global burden of common bacterial pathogens and their pathogenicity. This knowledge is required to improve immunization rates, improve the effectiveness of vaccines, and consider the impact of antimicrobial resistance when assessing the situation. Many bacteria have developed antimicrobial resistance, which has significant implications for infectious diseases and favors the survival of resilient microorganisms. This review emphasizes the significance of understanding the bacterial pathogens that cause this health threat on a global scale.

show abstract

Section: Strategies For Combating Antimicrobial Resistancementioning

confidence: 99%

Understanding bacterial pathogenicity: a closer look at the journey of harmful microbes

Soni,

Sinha,

Pandey

2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The worldwide economic cost of AMR by 2050 is estimated to reach as high as USD 100 trillion, underscoring the need to address this concern from an economic perspective [ 1 ]. In addition, a decreasing trend has been observed in the development of new antibiotic agents [ 2 ]. Thus, there is a need to curb the development of drug resistance in bacteria and preserve the availability of effective antibiotics for future generations.…”

Section: Introductionmentioning

confidence: 99%

Procalcitonin-Based Antibiotic Use for Neonatal Early-Onset Bacterial Infections: Pre- and Post-Intervention Clinical Study

Go,

Nagano,

Sato

et al. 2023

Antibiotics

View full text Add to dashboard Cite

We previously reported the 95th percentile cutoff value of the serum procalcitonin (PCT) reference curve for diagnosing early-onset bacterial infection. We aimed to verify the effectivity of these novel diagnostic criteria by comparing antibiotic use and incidence of early-onset bacterial infection between pre- and post-introduction periods. We included newborns admitted to our neonatal intensive care unit who underwent blood tests within 72 h after birth between 2018 and 2022. The neonates were divided into the pre-intervention (admitted before the introduction, n = 737) or post-intervention (admitted after the introduction, n = 686) group. The days of antibiotics therapy (DOT) per 1000 patient days up to 6 days after birth, percentage of antibiotic use, and incidence of early-onset bacterial infection were compared between the groups. The post-intervention group had significantly lower DOT per 1000 patient days (82.0 days vs. 211.3 days, p < 0.01) and percentage of newborns receiving antibiotics compared with the pre-intervention group (79 (12%) vs. 280 (38%), respectively, p < 0.01). The incidence of early-onset bacterial infections did not differ between the groups (2% each, p = 0.99). In conclusion, our diagnostic criteria using the 95th percentile cutoff value of the serum PCT reference curve for early-onset bacterial infection were proven safe and effective, promoting appropriate use of antibiotics.

show abstract

Recent advances and challenges in antibacterial drug development; The editorial

Abstract: Editorial

Cited by 2 publications

References 11 publications

Understanding bacterial pathogenicity: a closer look at the journey of harmful microbes

Understanding bacterial pathogenicity: a closer look at the journey of harmful microbes

Procalcitonin-Based Antibiotic Use for Neonatal Early-Onset Bacterial Infections: Pre- and Post-Intervention Clinical Study

Contact Info

Product

Resources

About